What does 95.2% purity on a wide-pore C18 column actually tell me about a mazdutide vial?

The particulars: 95.2% · a wide-pore C18 column · mazdutide.

I have the document in front of me and I can read the numbers. What I cannot do is interpret them.

I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.

What is the correct interpretation, and what is the common misreading?

Worth being precise here: gradient design is usually described as though it is a minor technical detail rather than the primary determinant of what the method measures.

Acetonitrile is the organic modifier of choice because it has a good UV cutoff, a reasonable viscosity and a refractive index that minimises baseline noise.

Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

Peptide impurities from solid-phase synthesis include deletion sequences, truncations from premature cleavage, racemised residues from epimerisation and oxidised variants, each of which may have different chromatographic behaviour.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

The relevant detail is that the limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

The 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.

Worth being precise here: temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.

Inter-laboratory studies using identical methods on identical material show precision well within half a per cent when the method is locked down, pointing to method variability as the primary source of disagreement.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

edited 12 Feb 2025 by meniscus_film — fixed an arithmetic slip in the third paragraph

Start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.

Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

Ask for the chromatogram and the system suitability data, not just the number.

Peak shape carries as much information as peak area does, and a badly tailing peak or a shouldered peak is telling you something about the sample or the column that matters.

Formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.

One qualification: the limit of detection on a reversed-phase HPLC is set by the noise on the baseline, which for these molecules is usually in the range of a tenth of one per cent or less, and anything smaller is not reproducibly detectable.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

edited 16 Dec 2024 by s_kalniete — reworded for clarity after a comment

High-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."

Mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.

I would caution against over-interpreting small differences between runs, because the noise floor of the method is larger than most people assume.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.